Benowitz LI, Goldberg DE, Madsen JR, et al. Inosine stimulates extensive axon collateral growth in the rat corticospinal tract after injury. Proc Natl Acad Sci USA 1999;96:13486-90. View abstract.

Starling RD, Trappe TA, Short KR, et al. Effect of inosine supplementation on aerobic and anaerobic cycling performance. Med Sci Sports Exerc 1996;28:1193-8. View abstract.

Williams MH, Kreider RB, Hunter DW, et al. Effect of inosine supplementation on 3-mile treadmill run performance and VO2 peak. Med Sci Sports Exerc 1990;22:517-22. View abstract.

Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141-50. View abstract.

Muñoz García D, Midaglia L, Martinez Vilela J, et al. Associated inosine to interferon: results of a clinical trial in multiple sclerosis. Acta Neurol Scand. 2015;131(6):405-10. View abstract.

Gonsette RE, Sindic C, D'hooghe MB, et al. Boosting endogenous neuroprotection in multiple sclerosis: The association of inosine and interferon beta in relapsing-remitting Multiple Sclerosis (ASIIMS) trial. Mult Scler. 2010;16(4):455-62. View abstract.

Markowitz CE, Spitsin S, Zimmerman V, et al. The treatment of multiple sclerosis with inosine. J Altern Complement Med. 2009;15(6):619-25. View abstract.

Toncev G. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. Vojnosanit Pregl. 2006;63(10):879-82. View abstract.

Yamamoto T, Moriwaki Y, Cheng J, Takahashi S, Tsutsumi Z, Ka T, Hada T. Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism. 2002;51(4):438-42. View abstract.

Watanabe H, Hattori T, Kume A, et al. Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine. Medicine (Baltimore) 2020;99(35):e21576. View abstract.

Camerini L, Ardais AP, Xavier J, et al. Inosine prevents hyperlocomotion in a ketamine-induced model of mania in rats. Brain Res 2020;1733:146721. View abstract.

Parkinson Study Group SURE-PD3 Investigators, Schwarzschild MA, Ascherio A, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA 2021;326(10):926-939. View abstract.

Teixeira FC, Gutierres JM, Soares MSP, et al. Inosine protects against impairment of memory induced by experimental model of Alzheimer disease: a nucleoside with multitarget brain actions. Psychopharmacology (Berl) 2020;237(3):811-823. View abstract.

Dalbeth N, Allan J, Gamble GD, et al. Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers. Arthritis Res Ther 2020;22(1):259. View abstract.

Dalbeth N, Horne A, Mihov B, et al. Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. Arthritis Rheumatol 2021;73(9):1758-1764. View abstract.

Kharitonova T, Shvarts YG, Verbovoy AF, Orlova NS, Puzyreva VP, Strokov IA. Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER). BMJ Open Diabetes Res Care 2022;10(3):e002785. View abstract.

Walk D, Nicholson K, Locatelli E, et al. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. Muscle Nerve 2023;67(5):378-386. View abstract.